Cocaine-antagonist effects of limited-efficacy D1 agonists.
Bergman
J
J
Harvard Medical School, New England Regional Primate Research Center, Southborough, MA 01772-9102.
Rosenzweig-Lipson
S
S
D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine / Q000494:pharmacology; D000818:Animals; D001552:Benzazepines / Q000494:pharmacology; D003042:Cocaine / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D003216:Conditioning, Operant / Q000187:drug effects; D015259:Dopamine Agents / Q000494:pharmacology*; D018492:Dopamine Antagonists; D017447:Receptors, Dopamine D1 / Q000187:drug effects*; D012055:Reinforcement Schedule; D012453:Saimiri
D001552:Benzazepines; D015259:Dopamine Agents; D018492:Dopamine Antagonists; D017447:Receptors, Dopamine D1; C058081:ecopipam; C052506:SK&F 75670; D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; D003042:Cocaine